Clinical trial
Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy
NCT00406458 · Sangamo Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00406458 |
|---|---|
| Title | Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy |
| Official title | A Phase 2 Repeat Dosing Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy |
| Lead sponsor | Sangamo Therapeutics, Industry |
| Collaborators | Juvenile Diabetes Research Foundation |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 1, Type 2, Diabetic Polyneuropathy |
| Intervention type | Drug, Other |
| Interventions | SB-509, Normal Saline |
| Enrollment | 110 |
| Start date | Nov 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | May 1, 2009 |
| First posted | Dec 4, 2006 |
| Last update posted | Nov 1, 2012 |
| Countries | Mexico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: